Novartis AG (NVS)

Every figure this model derived for NVS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,548,000,000 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 11,590,000,000 CashAndCashEquivalents 2025-12-31
current assets 30,460,000,000 CurrentAssets 2025-12-31
current liabilities 27,278,000,000 CurrentLiabilities 2025-12-31
equity 46,130,000,000 EquityAttributableToOwnersOfParent 2025-12-31
interest expense 1,144,000,000 InterestExpense 2025-12-31
ocf 19,144,000,000 CashFlowsFromUsedInOperatingActivities 2025-12-31
revenue 54,532,000,000 RevenueFromSaleOfGoods 2025-12-31
sbc 1,330,000,000 ExpenseFromSharebasedPaymentTransactionsWithEmployees 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up NVS on one particular measure came for.

RatioValue
cash operating margin36.54
current ratio1.12
current ratio reported1.12
ebit cagr15.09
ebit yoy21.31
ev ebit17.84
ev owner earnings19.36
ev sales5.77
fcf margin32.27
growth cv3.16
interest cover15.42
net debt ebitda1.06
operating margin32.36
owner earnings margin29.83
revenue growth8.38
revenue growth per share8.38
roic21.16
rule of 4040.73
sbc pct revenue2.44

What to be careful about

What this model itself distrusts about NVS's figures. Written by the derivation as it ran, not added afterwards.